Characteristics, Cardiovascular Comorbidity and Medicines Management in Patients with Type 2 Diabetes and CKD: Results of the IRIDIEM Study | Zendy

Paul E. Stevens | Zendy; Guntram Schernthaner | Zendy; S. Raptis | Zendy; Christoph Wanner | Zendy; Armin Scherhag | Zendy; Norbert Lameire | Zendy

Open Access

Characteristics, Cardiovascular Comorbidity and Medicines Management in Patients with Type 2 Diabetes and CKD: Results of the IRIDIEM Study

Author(s) -

Paul E. Stevens,

Guntram Schernthaner,

S. Raptis,

Christoph Wanner,

Armin Scherhag,

Norbert Lameire

Publication year - 2010

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000313595

Subject(s) - medicine , kidney disease , type 2 diabetes , diabetes mellitus , comorbidity , proteinuria , concomitant , population , endocrinology , kidney , environmental health

Type 2 diabetes is a leading cause of chronic kidney disease (CKD). The purpose of the Individual Risk-Profiling and Treatment in Diabetes Management (IRIDIEM) study was to evaluate the characteristics of CKD and associated comorbidities in patients with type 2 diabetes and CKD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research